HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum. HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, HIL-214, will be a topic of discussion.
|Fireside chat details:|
|Date:||Thursday, August 18, 2022|
|Time:||3:00 – 3:50 p.m. Eastern Daylight Time (EDT)|
|Moderator:||David Risinger, CFA|
|HilleVax Participant:||Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer|
Please contact your SVB Securities representative to view the session
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.